University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.
Today’s deal net round ups the smaller investments from across the university innovation ecosystem that have occurred over the holiday period.
Magnax raised the cash from investors including automotive parts firm Hirschvogel Automotive with a view of broadening R&D and entering new markets with its EV motor technology.
Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.